Physiological and pathological cardiac hypertrophy have directionally opposite changes in transcription of thyroid hormone (TH)-responsive genes, including ␣and ␤-myosin heavy chain (MyHC) and sarcoplasmic reticulum Ca 2ϩ -ATPase (SERCA), and TH treatment can reverse molecular and functional abnormalities in pathological hypertrophy, such as pressure overload. These findings suggest relative hypothyroidism in pathological hypertrophy, but serum levels of TH are usually normal. We studied the regulation of TH receptors (TRs) ␤1, ␣1, and ␣2 in pathological and physiological rat cardiac hypertrophy models with hypothyroid-and hyperthyroid-like changes in the TH target genes, ␣and ␤-MyHC and SERCA. All 3 TR subtypes in myocytes were downregulated in 2 hypertrophy models with a hypothyroid-like mRNA phenotype, phenylephrine in culture and pressure overload in vivo. Myocyte TR␤1 was upregulated in models with a hyperthyroid-like phenotype, TH (triiodothyronine, T3), in culture and exercise in vivo. In myocyte culture, TR overexpression, or excess T3, reversed the effects of phenylephrine on TH-responsive mRNAs and promoters. In addition, TR cotransfection and treatment with the TR␤1-selective agonist GC-1 suggested different functional coupling of the TR isoforms, TR␤1 to transcription of ␤-MyHC, SERCA, and TR␤1, and TR␣1 to ␣-MyHC transcription and increased myocyte size. We conclude that TR isoforms have distinct regulation and function in rat cardiac myocytes. Changes in myocyte TR levels can explain in part the characteristic molecular phenotypes in physiological and pathological cardiac hypertrophy. (Circ Res. 2001;89:591-598.) Key Words: thyroid hormone receptor Ⅲ physiological and pathological hypertrophy Ⅲ ␣ 1 -adrenergic receptor Ⅲ cardiac myocyte Ⅲ rat Original
C ardiac hypertrophy is sometimes considered a single process that leads invariably to myocardial dysfunction (pathological hypertrophy). However, physiological hypertrophy exists in which cardiac function is maintained or enhanced, including normal cardiac development, exercise training, and thyroid hormone (TH) treatment. Exercise and TH can reverse molecular and functional abnormalities in pathological hypertrophy without decreasing ventricular mass, indicating that physiological and pathological hypertrophy are qualitatively distinct processes. [1] [2] [3] [4] [5] [6] TH-responsive genes in cardiac muscle include ␣-myosin heavy chain (MyHC) and sarcoplasmic reticulum Ca 2ϩ -ATPase (SERCA), which are induced by TH, and ␤-MyHC, which is repressed. 7, 8 An intriguing observation is that pathological hypertrophy is characterized by hypothyroid-like changes in these target genes, with decreases in ␣-MyHC and SERCA and increases in ␤-MyHC, a molecular phenotype also called the fetal program. 9 The fact that TH treatment can reverse these genetic changes in some models of pathological hypertrophy is additional evidence for a hypothyroid state, but TH blood levels are usually normal. 3 Conversely, physiological hypertrophy caused by exercise is characterized by hyperthyroid-like changes in TH target genes, yet again blood TH levels are normal. 10 Only in cardiac hypertrophy during normal postnatal development are changes in TH-responsive genes attributable clearly to altered TH levels. 11, 12 Transcription of TH target genes is mediated by nuclear TH receptors (TRs), with 2 genes, ␣ and ␤, encoding at least 4 major TRs, ␤1, ␤2, ␣1, and ␣2, 13, 14 as well as minor variants, including TR␤3. 15 TRs ␤1, ␣1, and ␣2 are expressed widely. TR␤2 is present mainly in pituitary cells but might be a small fraction of T3-binding TRs in heart, as found in one study. 16 TR␣2 binds thyroid response elements (TREs) on DNA but does not bind 3,3Ј,5-triiodo-L-thyronine (T3), the active form of TH, and can function as a dominant negative. 13, 17 TRs ␤1 and ␣1 bind T3 with similar affinity but exhibit subtle differences in binding to TREs and cofactors and in forming homodimers and heterodimers with retinoid X receptors. 13,18 -20 Consistent with these biochemical differences, mouse TR knockouts reveal nonredundant TR functions in many tissues. 19 -21 In the heart, however, TR knockouts suggest that the transcription effects of TH are mediated largely by TR␣1. 17, 22 TR functions have not been evaluated systematically in isolated myocytes.
In this study, we tested the hypothesis that hypothyroidand hyperthyroid-like transcription changes in pathological and physiological hypertrophy are caused by altered TR levels in heart and myocytes. Recent studies in the aging rat and in human end-stage heart failure reveal changes in myocardial TR levels that correlate with changes in TH target gene transcription. 23, 24 However, possible changes in TR levels in hypertrophy have not been examined, and TR functions on target promoters in myocytes have not been compared. We measured TRs in rat hypertrophy models in culture and in vivo and tested TR functions in culture using transfection and treatment with T3 or a TR␤1-selective agonist.
Materials and Methods

Cell Culture, Hypertrophy, and Transfection
Ventricular myocytes from 1-day-old rats were plated at low density in MEM with 5% calf serum and studied in serum-free MEM exactly as in Deng et al. 25 Cardiac nonmyocytes in preplates were expanded to near confluence in MEM with 5% serum. 26 Cultures were treated with phenylephrine (PE) (Sigma No. P6126), T3 (Sigma No. T5516), GC-1 (gift from G. Chiellini and T.S. Scanlan, Department of Pharmaceutical Chemistry and Cellular and Molecular Pharmacology, University of California, San Francisco, Calif), 18 or their vehicles (ascorbic acid for PE, NaOH for T3, and DMSO for GC-1). Myocyte hypertrophy was quantified by content of radiolabeled protein (RLP) after continuous incubation with 14 C-or 3 Hphenylalanine. Myocytes were doubly transfected using calcium phosphate coprecipitation 27 with expression plasmids for the human TRs under control of the cytomegalovirus promoter (CMV) 28 and chloramphenicol acetyl transferase (CAT) reporter plasmids containing the rat promoters for ␣-MyHC (2900 bp), ␤-MyHC (3300 bp), or SERCA (3500 bp). 29 
Hypertrophy In Vivo
Hypertrophy was induced in adult male Wistar rats by voluntary wheel running for 10 weeks (age 7 to 17 weeks) or by ascending aortic constriction (pressure gradient Ϸ75 mm Hg) for 4 weeks (age 10 to 14 weeks). 30 Serum levels of total 3,3Ј,5,5Ј-tetraiodo-Lthyronine (T4) and total T3 were measured by ELISA (ICN Pharmaceuticals).
RNase Protection Assay (RPA) for TH-Responsive mRNAs
Total RNA was extracted from cells or ventricles with TRIZol (GIBCO) and used in RPA with a probe for ␣and ␤-MyHC and a probe for SERCA2a plus GAPDH as an internal control (see expanded Materials and Methods, available in the online data supplement at http://www.circresaha.org). 25 
TH Receptors
For TR mRNAs, RPA was used with probes specific for the rat TR isoforms, and GAPDH was used as an internal control (see the expanded Materials and Methods section). 24 For TR proteins, cul-tured myocyte nuclear and cytoplasmic fractions 27 were used in Western blot with monoclonal antibodies from Santa Cruz (J51/SC-737 specific for human TR␤1; J52/SC-738 reactive with rat and human TR␤1). 31 Human and rat TR␤1 proteins for standards were synthesized using rabbit reticulocyte lysate (TNT T7 Quick Coupled Transcription/Translation System, Promega). 28, 32 Statistics Data shown are meanϮSE and were compared by one-way ANOVA and the Newman-Keuls test.
An expanded Materials and Methods section can be found in the online data supplement available at http://www.circresaha.org.
Results
TH-Responsive mRNAs in Hypertrophy Models in Culture and In Vivo
We first confirmed regulation of TH target mRNAs in cardiac hypertrophy models in culture and in vivo ( Table 1 ). In cultured neonatal rat myocytes, TH (T3 100 nmol/L) caused hypertrophy, increased ␣-MyHC and SERCA mRNA levels, and repressed ␤-MyHC to 5% of control. The ␣ 1 -adrenergic receptor (AR) hypertrophic agonist PE (20 mol/L) had opposite effects on these mRNAs, increasing ␤-MyHC and decreasing SERCA and ␣-MyHC. Prazosin (2 mol/L) inhibited all PE effects, confirming ␣1-AR dependence (nϭ3 cultures, data not shown).
Under our basal, serum-free culture conditions, medium T3 levels averaged about 0.1 nmol/L over the 3-day time course of these experiments, presumably reflecting myocyte release of stored T3. [33] [34] [35] Interestingly, when 1000-fold excess T3 (100 nmol/L) was added to PE-treated myocytes, all PE effects on TH-responsive transcripts were reversed, with significant increases in ␣-MyHC and SERCA and decreases in ␤-MyHC (Table 1 ). The antagonistic relationship between ␣1-AR and T3 signaling was not explained by a lesser degree of hypertrophy, because hypertrophy was even greater with PE plus T3 (Table 1) .
In intact rat hypertrophy models, voluntary running exercise stimulated hypertrophy with an mRNA profile similar to T3 in culture (Table 1) . Conversely, pressure overload by ascending aortic constriction caused hypertrophy with changes in TH target mRNAs opposite to exercise and similar to PE in culture (Table 1) . Thus, in agreement with previous studies (discussed in the Introduction), 2 hypertrophy models had signature mRNA changes of heightened thyroid signaling, T3 in culture and exercise in vivo. In contrast, 2 other models had a directionally opposite pattern of hypothyroidlike signaling, PE in culture and pressure overload in vivo. T3 and T4 blood levels in the intact rat models were similar among all 4 groups, with total T4 Ϸ40 nmol/L (3 to 3.2 g/dL) and total T3 Ϸ1 nmol/L (52 to 55 ng/dL) (nϭ6 to 13, PϭNS), as found by others. 3, 10 Thus, mRNA changes were not explained by changes in circulating TH concentration.
TR Levels in Hypertrophy Models in Culture
To test if some change in thyroid signaling besides TH concentration might explain changes in transcription of THresponsive genes in hypertrophy, we first measured TR levels in cultured myocytes. In cultured myocytes under basal, serum-free conditions, RPAs detected the mRNAs for TRs ␣2, ␣1, and ␤1, with a molar ratio of Ϸ7:3:1. TR␤2 mRNA was not found, using a probe validated in rat pituitary GC cells (not shown), and TR␤3 was not tested. Treatment with T3 under conditions that stimulated hypertrophy (Table 1) caused an increase in TR␤1 mRNA, with a maximum Ϸ2-fold and an EC50 Ϸ3 nmol/L, but had no effect on TR␣2 or ␣1 ( Figure 1A ). T3 induction of TR␤1 in myocytes was significant as early as 12 hours and maximum at 48 hours (data not shown). Thus TR␤1 itself was a TH-responsive gene in myocytes and was increased in T3-stimulated hypertrophy.
PE-induced hypertrophy in cultured myocytes had an effect different from T3 and reduced the levels of all 3 TR isoform mRNAs to 50% to 75% of control ( Figure 1B) . The EC50 for TR repression was about 3 mol/L ( Figure 1B) , similar to the EC50 for PE-induced hypertrophy, and the PE effect was detected as early as 6 hours (data not shown). PE is an ␣1-AR agonist with weak ␤-AR activity, and specific ␣1-AR repression of TRs was confirmed in separate experiments with norepinephrine, isoproterenol, prazosin, and timolol (all 2 mol/L, nϭ3 to 4 cultures for each, data not shown). Interestingly, and similar to the other TH target mRNAs ( Table 1) , addition of T3 reversed PE repression of TR␤1, but TRs ␣1 and ␣2 were not changed ( Figure 1B) .
To test if TR mRNA levels reflected TR protein, we measured endogenous TRs in cultured myocytes by Western blot. None of the commercial antibodies from Santa Cruz or Affinity BioReagent gave specific signals for TRs ␣1 and ␣2 (not shown), but TR␤1 protein was detected in nuclear extracts ( Figure 1 ). PE reduced TR␤1 protein significantly, whereas T3 increased TR␤1 and reversed TR␤1 repression caused by PE ( Figures 1A and 1B ). Thus TR␤1 mRNA and protein changes were concordant.
Cultured cardiac nonmyocytes also expressed mRNAs for all 3 of the TRs found in myocytes, ␣1, ␣2, and ␤1, but levels were not altered by PE 20 mol/L or T3 100 nmol/L (nϭ3 cultures, data not shown). No response to PE can be explained by the absence of ␣1-ARs in nonmyocytes. 36 No response to T3 is compatible with a requirement for cellspecific factors such as MEF-2 in myocyte TR signaling. 37, 38 
TR mRNA Levels in Hypertrophy Models In Vivo
Control adult male rat hearts contained mRNAs for TRs ␣2, ␣1, and ␤1 at equal molar ratios (Ϸ1:1:1). Physiological hypertrophy stimulated by voluntary running exercise mimicked T3 in culture, with an increase in TR␤1 mRNA and no change in TRs ␣1 and ␣2 ( Figure 2 ). Pathological hypertrophy stimulated by ascending aortic constriction was similar to PE in culture, with decreases in all 3 TR isoform mRNAs ( Figure 2 ), detectable as early as 1 week after banding (not shown). Thus, in distinct hypertrophy models in vivo as in culture, TR isoform levels and TH-responsive transcript levels were related directly ( Figure 2 and Table 1 ).
Cotransfection of TR Isoforms and TH-Responsive Promoters
To test directly whether changes in TR levels could alter TH-responsive transcription, we cotransfected cultured myo- In culture, neonatal rat cardiac myocytes were treated with vehicle, T3, or PE for 72 hours; in the PEϩT3 group, T3 was also present for the final 24 hours. RLP was an index of hypertrophy, and MyHC and SERCA mRNAs were quantified by RNase protection in 3 g total RNA. In adult male rats, hypertrophy was induced by voluntary running exercise (Ex) for 10 weeks or ascending aortic constriction (AC) for 4 weeks, and left ventricular (LV) mRNAs were quantified as in culture. The mRNA levels are normalized to the vehicle or sedentary groups. cytes with expression plasmids for the human TR isoforms and reporter plasmids for the TH-responsive genes (Figure 3 ). The Western blot in Figure 3A shows that human TR␤1 was detected in nuclear extracts from TR␤1-transfected myocytes, with overflow of transfected TR␤1 into the cytosolic fraction, suggesting saturating levels. 31 Similarly, an antibody recognizing both human and rat TR␤1 indicated that total TR␤1 nuclear levels in transfected cultures were about 2-fold over endogenous ( Figure 3A ). With Ϸ5% of myocytes transfected, 39 this result implied about 40-fold overexpression of TR␤1. We used this system to test the effects of increasing TR isoform levels on ␣-MyHC, ␤-MyHC, and SERCA promoters. In vehicle-treated control myocytes, overexpression of TR␣1 activated the ␣-MyHC promoter, and TR␤1 repressed ␤-MyHC ( Figure 3B ). TR␣2 had no effect. Induction of ␣-MyHC indicated that TR␣1 was expressed, even though Western blots were unsatisfactory for TR␣ protein levels.
In PE-treated myocytes transfected with empty vector, the ␤-MyHC promoter was activated, and ␣-MyHC and SERCA promoters were repressed ( Figure 3C ), similar to the PE effects on endogenous mRNAs (Table 1 ). Increasing the levels of TR␣1 by transfection reversed PE repression of ␣-MyHC, whereas TR␤1 overexpression significantly op-posed the effects of PE on both ␤-MyHC and SERCA. Interestingly, forced expression of TR␣2, the non-T3-binding TR, slightly but significantly enhanced PE repression of ␣-MyHC and SERCA ( Figure 3C) .
In T3-treated myocytes transfected with empty vector, the ␤-MyHC promoter was repressed and ␣-MyHC and SERCA were activated ( Figure 3D ), as expected from T3-induced mRNA changes ( Table 1 ). Overexpression of TR␤1 in T3-treated myocytes significantly enhanced induction of the SERCA promoter, but TRs ␣1 and ␣2 had no effects over T3 alone ( Figure 3D ).
Taken together, these cotransfection results showed that increasing the levels of T3-binding TRs altered THresponsive transcription and antagonized the effects of PE on TH-responsive genes. In addition, the results suggested different functions of TRs in myocytes, regulation of ␣-MyHC by TR␣1, and regulation of ␤-MyHC and SERCA by TR␤1. The repressive effect of TR␣2 only in PE-treated cells Cultured neonatal rat cardiac myocytes were treated with T3 (A) or PE (B) for 72 hours, and TR isoform mRNAs were assayed in 10 g total RNA by RNase protection (left and middle). Alternatively, cells were treated for 120 hours, and TR␤1 protein in equal numbers of myocyte nuclei was quantified by Western blot (right). In the PEϩT3 groups, cells treated with PE 20 mol/L were also treated with T3 100 nmol/L for the final 24 hours (mRNA) or 72 hours (protein). Representative gels are shown; mean data are from 5 cultures for mRNA and 3 cultures for protein.
Figure 2. Regulation of TR isoforms with hypertrophy in vivo.
Hypertrophy was induced in adult male rats by voluntary running exercise (Ex) for 10 weeks or ascending aortic constriction (AC) for 4 weeks, and left ventricular TR isoform mRNAs were assayed as in Figure 1 . Top, Representative gel is shown. Bottom, Mean values from the indicated numbers of rats, normalized to the sedentary control group.
( Figure 3C ) was consistent with a weak dominant-negative effect of this non-T3-binding TR (see the Introduction) that could be detected only when levels of the T3-binding TRs were reduced by PE ( Figure 1B ).
Effects of a TR␤1-Selective Agonist on Myocyte Transcription and Hypertrophy
To test different functional roles for TR isoforms by a second approach not involving transfection, we treated myocytes with GC-1, which has Ϸ10-fold selectivity for TR␤1 versus TR␣1 but has not been tested with TRs ␤2 and ␤3, and compared the responses to T3, which binds with similar affinity to both TRs ␤1 and ␣1. 18, 35 We assayed both TH-responsive promoter activities and endogenous mRNAs (Figures 4A and 4B) and also RLP, an index of total protein content or overall myocyte size ( Figure 4C ). As shown in Figures 4A through 4C and summarized in Table 2 , the EC50s for GC-1 induction of SERCA and repression of ␤-MyHC were identical to the EC50s for T3, whereas GC-1 was at least 10-fold less potent than T3 in induction of ␣-MyHC and RLP. These data were consistent with the cotransfection experiments ( Figure 3 ) and suggested preferential coupling of TR␤1 to ␤-MyHC and SERCA, whereas TR␣1 regulated ␣-MyHC and total protein content. In addition, GC-1 increased TR␤1 mRNA by 203Ϯ28% at 100 nmol/L with an EC50 of 2 nmol/L (PϽ0.05 versus vehicle, nϭ5), almost identical to the effect of T3 (Figure 1 and Table  2 ), consistent with the notion that TR␤1 activated its own transcription.
Discussion
The main new finding in this study was the direct relationship between TR levels and transcription of TH-responsive genes in different types of hypertrophy. All TRs were downregulated in pressure overload, a model of pathological hypertrophy with a hypothyroid-like molecular phenotype. Conversely, TR␤1 was upregulated in the exercise model of physiological hypertrophy, where TH-responsive transcription was enhanced. These results, together with the TR overexpression experiments in cultured myocytes, suggest that the distinct molecular signatures in different types of hypertrophy can be caused in part by altered TR levels. Thus the fetal program in pathological hypertrophy can be viewed as the result of cellular hypothyroidism, caused by reduced TR levels, whereas physiological hypertrophy can be seen as a state of relative cellular hyperthyroidism, attributable to increased TR␤1. The results also indicate that TR isoforms have different transcription functions in rat myocytes and raise the possibility of additional alteration of TH signaling in hypertrophy.
We detected 3 TRs in rat myocytes, ␤1, ␣1, and ␣2, and all were reduced by pressure overload in vivo and ␣1-AR signaling in culture (Figures 1 and 2) , the models with hypothyroid-like transcription changes ( Table 1 ). Reversal of hypothyroid signaling when TRs ␤1 and ␣1 were overexpressed in the PE culture model supported the causal significance of TR downregulation ( Figure 3C ). Downregulation of dominant-negative TR␣2 in both models would have been expected to partly counteract the hypothyroid effects of decreased TRs ␤1 and ␣1, because overexpressed TR␣2 had hypothyroid effects when TRs ␤1 and ␣1 were reduced by PE ( Figure 3C ). Nevertheless, global TR downregulation in both EC50s were estimated from the dose-response curves in Figures 1A and 4A through 4C. The curve for TR␤1 mRNA induction by GC-1 is not shown, and TR␤1 promoter activity was not tested. GC-1 is at least 10-fold less potent than T3 in stimulation of ␣-MyHC and RLP; the true EC50s for GC-1 induction of ␣-MyHC and RLP might be even higher, because the responses are not quite saturated at the highest doses studied ( Figures 4B and 4C ). models of pathological hypertrophy was associated with reduced transcription of TH target genes.
Abnormal TR levels are also seen at a terminal stage of pathological hypertrophy, severe human heart failure. In human heart failure, TR␣1 is decreased and TR␣2 is increased, probably because of altered splicing of the TR␣ gene, and the increase in TR␣2 correlates with reduced ␣-MyHC transcription. 24 In our rat models of PE treatment and pressure overload, the global decrease in all TR mRNAs could be explained by reduced TR gene transcription or increased TR mRNA degradation. Thus the specific mechanism for altered TR levels might differ among species or models, but the human and rat studies both suggest that TR downregulation is a mechanism for hypothyroid-like signaling in pathological hypertrophy. This relationship was additionally strengthened by our converse results in physiological models.
TR upregulation was seen in exercise, a model of physiological hypertrophy with normal or enhanced contractile function. 30 Voluntary running exercise caused an increase in TR␤1 but no change in TR␣ ( Figure 2 ). T3 in culture also caused selective induction of TR␤1 ( Figure 1 ) and similarly induces a physiological hypertrophy in vivo. 5 Our finding that the TR␤1 gene is TH-responsive in myocytes but the TR␣ gene is not agrees with some studies in the intact rat, 40,41 but not with others, 42 and can be explained by positive TREs in the TR␤1 promoter that are absent in TR␣. 43, 44 Furthermore, the TR␤1 gene seemed to be activated by TR␤1 itself, because T3 and the TR␤1-selective agonist GC-1 induced TR␤1 with similar potency (Table 2) . Thus, exercise-induced increases in TR␤1 levels should be partly self-sustaining, and the increase in TR␤1 would augment transcription of downstream TH target genes on the basis of our transfection studies ( Figure 3 ). TR␤1 in myocytes differed from TR␣1 in induction by T3 and also in function. In this study, we made the first systematic comparison of TR function in isolated myocytes and found by 2 complimentary approaches that TR␤1 induced SERCA and TR␤1 itself and repressed ␤-MyHC, whereas TR␣1 increased ␣-MyHC and protein content (Figures 3 and 4 and Table 2 ). Notably, the same pattern of TR function was seen with TR cotransfection and with GC-1, which has Ϸ10-fold selectivity for TR␤1. 18 Distinct TR isoform effects on different promoters might be explained by isoform-specific interactions with cofactors or differing affinities for TREs (see the Introduction). Interestingly, target gene-specific differences were evident even for a single TR isoform in that TR␤1 more potently repressed ␤-MyHC than it activated SERCA and activated SERCA more potently than TR␤1 itself (Table 2) . Also intriguing was the correlation of TR␣1 signaling with increased total protein content, an index of overall hypertrophy ( Figure 4C and Table 2 ). Increased protein content requires increased translation as well as transcription, thus raising the question of nongenomic effects of T3 via TR␣1.
Previous results from rat and human models are consistent with the distinct transcription functions of TR isoforms we show in this study. In the aging rat, increased ␤-MyHC transcription correlates with decreased TR␤1 levels and reduced ␣-MyHC correlates with reduced TR␣1. 23 A correlation between levels of TR␣1 and ␣-MyHC is also seen in the failing human heart. 24 A preferential effect of GC-1 on myocardial SERCA and ␤-MyHC is not seen in the rat in vivo, but this might be because of lower bioavailability of GC-1 in cardiac tissue. 35 On the other hand, the mouse might be different from rat and human, because knockout studies suggest that most cardiac effects of T3 can be accounted for by TR␣1. 17, 22 Whether both TRs are required for full TH effects in heart is one key consideration in potential therapeutic uses of TH signaling, 8 and additional study is needed.
Finally, the question arises of whether other mechanisms alter TH signaling in hypertrophy in addition to changes in TR levels. Pertinent is the effect of T3 in the culture model, where a 1000-fold increase in medium T3 (from 0.1 to 100 nmol/L) reversed PE antagonism of all TH-responsive genes, including the MyHCs, SERCA, and TR␤1, despite PE reduction of TR levels ( Table 1 and Figure 1 ). Thus, excess T3 in culture could counteract the hypothyroid effects of reduced TRs. In vivo as well, high doses of T3 reverse hypothyroid transcription in pressure overload models 3, 5 despite the reduced TR levels we show in this study ( Figure 2) . The reversal effect of excess T3 can be explained partly by induction of TR␤1 and downstream changes in other THresponsive genes, but the T3 effect also suggests that cellular T3 levels might be limiting in some cases. Thus it is possible that myocyte T3 metabolism [33] [34] [35] is changed in hypertrophy, with increases in cellular T3 with exercise and decreases with pressure overload and PE, and this requires additional study.
In summary, changes in TR levels can explain at least in part the characteristic hypothyroid-and hyperthyroid-like transcription in different types of hypertrophy. TH signaling is impaired in pathological hypertrophy and enhanced in physiological hypertrophy.
